Inventiva SA Stock
€4.23
Your prediction
Inventiva SA Stock
Pros and Cons of Inventiva SA in the next few years
Pros
Cons
Performance of Inventiva SA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Inventiva SA | -1.180% | 9.728% | 22.431% | 5.486% | -5.791% | - | - |
| Immunic Inc. | -3.970% | 0.729% | 12.000% | -2.167% | -15.054% | -92.675% | - |
| NanoViricides Inc. | -0.940% | 1.942% | 9.375% | -25.373% | -1.130% | -64.286% | -80.978% |
| Ocuphire Pharma Inc. | 4.210% | -7.348% | -2.820% | -12.075% | -13.313% | - | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Inventiva, a company operating in the biotechnology and medical research industry, seems to be continually investing in research and development, which is essential for growth in this sector. At first glance, the company's financials indicate a focus on innovation and expansion. However, a detailed analysis is necessary to determine the strengths and weaknesses in Inventiva's financial performance throughout the years.
R&D Expenditure: Inventiva consistently allocates a significant portion of its resources to research and development activities. For instance, it spent €60,469,000 in 2022, €48,452,000 in 2021, and €23,717,000 in 2020. High research investment is vital for the success of biotechnology firms and indicates a pledge to create groundbreaking solutions in the medical field.
Asset Growth: Inventiva's total assets have moderately increased from €121,985,000 in 2021 to €116,004,000 in 2022. A strong asset base can provide more opportunities for the company to leverage resources for growth initiatives.
